Form 8-K - Current report:
SEC Accession No. 0001104659-22-079655
Filing Date
2022-07-14
Accepted
2022-07-13 21:57:05
Documents
15
Period of Report
2022-07-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2220905d1_8k.htm   iXBRL 8-K 40121
2 EXHIBIT 2.1 tm2220905d1_ex2-1.htm EX-2.1 834116
3 EXHIBIT 10.1 tm2220905d1_ex10-1.htm EX-10.1 284866
4 EXHIBIT 10.2 tm2220905d1_ex10-2.htm EX-10.2 34128
  Complete submission text file 0001104659-22-079655.txt   1584043

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tbph-20220713.xsd EX-101.SCH 3039
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20220713_lab.xml EX-101.LAB 34476
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20220713_pre.xml EX-101.PRE 22599
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2220905d1_8k_htm.xml XML 3621
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 221082138
SIC: 2834 Pharmaceutical Preparations